Candida tropicalis in human disease

Critical Reviews in Microbiology

Volumn 36, Issue 4, 2010, Pages 282-298

  Ann Chai, Louis Yi ^a,c   Denning, David W ^b   Warn, Peter ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candida tropicalis; Candidiasis; Candidosis

Indexed keywords

AMPHOTERICIN B; ASPARTIC PROTEINASE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VIRULENCE FACTOR; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; APACHE; BIOFILM; BLOODSTREAM INFECTION; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; FUNGAL VIRULENCE; FUNGEMIA; FUNGUS IDENTIFICATION; HOSPITAL INFECTION; HUMAN; INVASIVE CANDIDIASIS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SUPERFICIAL MYCOSIS; TAXONOMY; VULVOVAGINITIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA TROPICALIS; CANDIDIASIS, INVASIVE; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS;

EID: 77957988813     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2010.489506     Document Type: Review

References (196)

1. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). (2008). EUCAST defnitive document EDef 7 1: method for the determination of broth dilution MICs of anti-fungal agents for fermentative yeasts 1499. Clin Microbiol Infect 14, 398-405.
2. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. (1997). Te epidemiology of hematogenous candidiasis caused by diferent Candida species. Clin Infect Dis 24, 1122-1128. (Pubitemid 127774267)
3. Alexander B D, Byrne T C, Smith K L, Hanson K E, Anstrom K J, Perfect. J R, Reller L B. (2007). Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 45, 698-706.
4. Almirante B, Rodriguez D, Park B J, Cuenca-Estrella M, Planes A M, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin S K, Morgan J, Rodriguez-Tudela. J L, Warnock D W, Pahissa A. (2005). Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance barcelona Spain from 2002 to 2003. J Clin Microbiol 43, 1829-1835.
5. Alvarez-Gasca M A, Arguero-Licea B, Pliego-Castaneda A, Garcia-Tena S. (1998). Fungal agents isolated from cancer patients. Rev Latinoam Microbiol 40, 15-24.
6. Antoniadou A, Torres H A, Lewis R E, Tornby J, Bodey G P, Tarrand. J P, Han X Y, Rolston K V, Safdar A, Raad I I, Kontoyiannis D P. (2003). Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82, 309-321.
7. Arathoon E G, Gotuzzo E, Noriega L M, Berman R S, DiNubile M J, Sable C A. (2002). Randomized double-blind multicenter study of caspofungin versus amphotericin B for treatment of oropharyn-geal and esophageal candidiases. Antimicrob Agents Chemother 46, 451-457. (Pubitemid 34087195)
8. Arendrup M, Horn T, Frimodt-Moller N. (2002). In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30, 286-291.
9. Arthington-Skaggs B A, Lee-Yang W, Ciblak M A, Frade. J P, Brandt M E, Hajjeh R A, Harrison L H, Sofair A N, Warnock D W. (2002). Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fuconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother, 46 2477-2481.
10. Asmundsdottir L R, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. (2008). Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 47, e17-e24.
11. Barchiesi F, Calabrese D, Sanglard D, Falconi-Di-Francesco L, Caselli F, Giannini D, Giacometti A, Gavaudan S, Scalise G. (2000). Experimental induction of fuconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 44, 1578-1584.
12. Barchiesi F, Colombo A L, McGough D A, Fothergill A W, Rinaldi M G. (1994). In vitro activity of itraconazole against fuconazole-sus-ceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodefciency virus. Antimicrob Agents Chemother 38, 1530-1533. (Pubitemid 24203564)
13. Bastide C, Carcenac A, Arrova F, Rossi D. (2005). Prostatic abscess due to Candida tropicalis. Prostate Cancer Prostatic Dis 8, 296-297.
14. Benson P M, Roth R R, Hicks C B, 1987 Nodular subcutaneous abscesses caused by Candida tropicalis. J Am Acad Dermatol 16, 623-624.
15. Bille J, Glauser M P. (1997). Evaluation of the susceptibility of pathogenic Candida species to fuconazole Fluconazole Global Susceptibility Study Group. Eur. J Clin Microbiol Infect Dis 16, 924-928.
16. Bistoni F, Vecchiarelli A, Cenci E, Sbaraglia G, Perito S, Cassone A, 1984 A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia 22, 409-418. (Pubitemid 14013124)
17. Bizerra F C, Nakamura C V, de P C, Estivalet Svidzinski T I, Borsato Quesada R M, Goldenberg S, Krieger M A, Yamada-Ogatta S F. (2008). Characteristics of bioflm formation by Candida tropicalis and antifungal resistance FEMS. Yeast Res 8, 442-450.
18. Blandin G, Ozier-Kalogeropoulos O, Wincker P, Artiguenave F, Dujon B. (2000). Genomic exploration of the hemiascomycetous yeasts: 16 Candida tropicalis. FEBS Lett 487, 91-94. (Pubitemid 32008724)
19. Borg-von-Zepelin M, Meyer I, Tomssen R, Wurzner R, Sanglard D, Telenti A, Monod M. (1999). HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113, 747-751.
20. Borman A M, Linton C J, Miles S J, Johnson E M. (2008). Molecular identifcation of pathogenic fungi. J Antimicrob Chemother 61, Suppl 1 i7-12.
21. Burnie. J P, Odds F C, Lee W, Webster C, Williams. J D, 1985 Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med. J (Clin Res Ed ) 290, 746-748.
22. Casalinuovo I A, Di F P, Garaci E. (2004). Fluconazole resistance in Candida albicans: a review of mechanisms. Eur Rev Med Pharmacol Sci 8, 69-77.
23. Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. (2008). Nosocomial candidaemia in children: results of a 9-year study. Mycoses 51, 248-257.
24. Chai Y A, Wang Y, Khoo A L, Chan F Y, Chow C, Kumarasinghe G, Singh K, Tambyah P A. (2007). Predominance of Candida tropica-lis bloodstream infections in a Singapore teaching hospital. Med Mycol 45, 435-439.
25. Chakrabarti A, Reddy T C, Singhi S. (1997). Does candiduria predict candidaemia? Indian J Med Res 106513-6-6.
26. Chen C Y, Chen Y C, Tang. J L, Yao M, Huang S Y, Tsai W, Chen Y C, Shen M C, Wang C H, Tien H F. (2003). Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence treatment and prognosis. Ann Hematol 82, 93-97.
27. Cheng Y R, Lin L C, Young T G, Liu C E, Chen C H, Tsay R W. (2006). Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 39, 155-161.
28. Chou H H, Lo H J, Chen K W, Liao M H, Li S Y. (2007). Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fuco-nazole. Diagn Microbiol Infect Dis 58, 427-433.
29. Chowdhary A, Becker K, Fegeler W, Gugnani H C, Kapoor L, Randhawa V S, Mehta G. (2003). An outbreak of candidemia due to Candida tropicalis in a neonatal intensive care unit. Mycoses 46, 287-292.
30. Chryssanthou E. (2001). Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J Clin Microbiol 39, 4181-4183.
31. Chryssanthou E, Cuenca-Estrella M. (2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 40, 3841-3844.
32. Cole G T, Halawa A A, Anaissie E J. (1996). Te role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 22, Suppl 2S73-88-88
33. Cooke V M, Miles R J, Price R G, Midgley G, Khamri W, Richardson A C. (2002). New chromogenic agar medium for the identifcation of Candida spp. Appl Environ Microbiol 68 3622-3627.
34. Costa C R, de Lemos. J A, Passos X S, de Araujo C R, Cohen A J, Souza L K, Silva M R. (2006). Species distribution and antifungal susceptibility profle of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia 162, 45-50.
35. Costa S F, Marinho I, Araujo E A, Manrique A E, Medeiros E A, Levin A S. (2000). Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect 45, 69-72.
36. Cuenca-Estrella M, Lee-Yang W, Ciblak M A, Arthington-Skaggs B A, Mellado E, Warnock D W, Rodriguez-Tudela. J L. (2002). Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother 46, 3644-3647.
37. Cuenca-Estrella M, Moore C B, Barchiesi F, Bille J, Chryssanthou E, Denning D W, Donnelly. J P, Dromer F, Dupont B, Rex. J H, Richardson M D, Sancak B, Verweij P E, Rodriguez-Tudela. J L. (2003). Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 9, 467-474.
38. d'Enfert C. (2009). Hidden killers: persistence of opportunistic fungal pathogens in the human host. Curr Opin Microbiol 12, 358-364.
39. Dannaoui E, Paugam A, Develoux M, Chochillon C, Matheron J, Datry A, Bouges-Michel C, Bonnal C, Dromer F, Bretagne S. (2010). Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine diferent hospital laboratories. Clin Microbiol Infect 16, 863-869.
40. de la Torre P, Reboli A C. (2007). Anidulafungin: a new echinocandin for candidal infections. Expert Rev Anti Infect Ter 5, 45-52.
41. De-Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schafer W, Cassone A. (1999). Evidence that members of the secretory aspar-tyl proteinase gene family in particular SAP2 are virulence factors for Candida vaginitis. J Infect Dis 179, 201-208.
42. de-Repentigny L, Phaneuf M, Mathieu L G. (1992). Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 60, 4907-4914.
43. Denning D W, Kibbler C C, Barnes R A. (2003). British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 3, 230-240.
44. Doebbeling B N, Lehmann P F, Hollis R J, Wu L C, Widmer A F, Voss A, Pfaller M A. (1993). Comparison of pulsed-feld gel electrophore-sis with isoenzyme profles as a typing system for Candida tropi-calis. Clin Infect Dis 16, 377-383.
45. Doi M, Homma M, Chindamporn A, Tanaka K. (1992). Estimation of chromosome number and size by pulsed-feld gel electrophoresis (PFGE). in medically important Candida species. J Gen Microbiol 138, 138-51.
46. Dorko E, Jenca A, Pilipcinec E, Danko J, Svicky E, Tkacikova L. (2001). Candida-associated denture stomatitis. Folia Microbiol (Praha) 46, 443-446.
47. Dorko E, Kmet'ova M, Marossy A, Dorko F, Molokacova M. (1999). Non-albicans Candida species isolated from plastic devices. Mycopathologia 148, 117-122.
48. Dorko E, Viragova S, Pilipcinec E, Tkacikova L. (2003). Candida-agent of the diaper dermatitis? Folia Microbiol (Praha) 48, 385-388.
49. Ellis D. (2002). Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49, Suppl A 7-10.
50. Elving G J, van der Mei H C, Busscher H J, van Weissenbruch R, Albers F W. (2002). Comparison of the microbial composition of voice prosthesis bioflms from patients requiring frequent versus infrequent replacement. Ann Otol Rhinol Laryngol 111, 200-203.
51. Elving G J, van der M H, Busscher H, van Weissenbruch R, Albers F. (2003). Infuence of diferent combinations of bacteria and yeasts in voice prosthesis bioflms on air fow resistance. Antonie Van Leeuwenhoek 83, 45-55.
52. Espinel-Ingrof A. (1998). In vitro activity of the new triazole voricona-zole (UK-109496). against opportunistic flamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36, 198-202.
53. Espinel-Ingrof A, Canton E, Peman J, Rinaldi M G, Fothergill A W. (2009). Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document). in three laboratories: results obtained with 2162 clinical isolates of Candida spp and other yeasts. J Clin Microbiol 47, 2766-2771.
54. Espinel-Ingrof A, Quart A, Steele-Moore L, Metcheva I, Buck G A, Bruzzese V L, Reich D. (1996). Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fuconazole therapy. J Med Vet Mycol 34, 111-116.
55. Espinel-Ingrof A, Vazquez. J A, Boikov D, Pfaller M A. (1999). Evaluation of DNA-based typing procedures for strain categorization of Candida spp. Diagn Microbiol Infect Dis 33, 231-239.
56. Feman S S, Nichols. J C, Chung S M, Teobald T A. (2002). Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc 100, 67-70.
57. Fenn. J P, Segal H, Barland B, Denton D, Whisenant J, Chun H, Christoferson K, Hamilton L, Carroll K. (1994). Comparison of updated Vitek Yeast Biochemical Card and API 20C yeast identi-fcation systems. J Clin Microbiol 32, 1184-1187.
58. Fisher. J F, Newman C L, Sobel. J D. (1995). Yeast in the urine: solutions for a budding problem. Clin Infect Dis 20, 183-189.
59. Fitzpatrick D A, Logue M E, Stajich. J E, Butler G. (2006). A fungal phy-logeny based on 42 complete genomes derived from supertree and combined gene analysis. BMC Evol Biol 6, 99.
60. Fleck R, Dietz A, Hof H. (2007). In vitro susceptibility of Candida species to fve antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 59, 767-771.
61. Flynn P M, Marina N M, Rivera G K, Hughes W T. (1993). Candida tropicalis infections in children with leukemia. Leuk Lymphoma 10, 369-376.
62. Foongladda S, Sakulmaiwatana P, Petlum P, Vanprapar N. (2004). Candida species genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Tailand during 1999-2002. J Med Assoc Tai 87, 92-99.
63. Fraser V J, Jones M, Dunkel J, Storfer S, Medof G, Dunagan W C. (1992). Candidemia in a tertiary care hospital: epidemiology risk factors and predictors of mortality. Clin Infect Dis 15, 414-421.
64. Freydiere A M, Buchaille L, Gille Y. (1997). Comparison of three commercial media for direct identifcation and discrimination of Candida species in clinical specimens Eur. J Clin Microbiol Infect Dis 16, 464-467.
65. Fridkin S K, Kaufman D, Edwards. J R, Shetty S, Horan T. (2006). Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 117, 1680-1687.
66. Fromtling R A, Abruzzo G K, Giltinan D M, 1987 Candida tropica-lis infection in normal diabetic and neutropenic mice. J Clin Microbiol 25, 1416-1420.
67. Goldani L Z, Mario P S. (2003). Candida tropicalis Fungemia in a Tertiary Care Hospital. J Infect 46, 155-160.
68. Gottfredsson M, Vredenburgh. J J, Xu J, Schell W A, Perfect. J R. (2003). Candidemia in women with breast carcinoma treated with highdose chemotherapy and autologous bone marrow transplantation. Cancer 98, 24-30.
69. Gronemeyer P S, Weissfeld A S, Sonnenwirth A C, 1982 Purulent pericarditis complicating systemic infection with Candida tropicalis. Am J Clin Pathol 77, 471-475.
70. Guo S, Bhattacharjee. J K. (2006). Novel lysine biosynthetic gene sequences (LYS1 and LYS5). used as PCR targets for the detection of the pathogenic Candida yeast. Appl Microbiol Biotechnol 72, 416-420.
71. Gupta N, Haque A, Lattif A A, Narayan R P, Mukhopadhyay G, Prasad R. (2004). Epidemiology and molecular typing of Candida isolates from burn patients. Mycopathologia 158, 397-405.
72. Hasenclever H F, Mitchell W O, 1961 Pathogenicity of C albicans and C tropicalis. Sabouraudia 1, 16-21.
73. Heelan. J S, Sotomayor E, Coon K, D'Arezzo. J B. (1998). Comparison of the rapid yeast plus panel with the API20C yeast system for identifcation of clinically signifcant isolates of Candida species. J Clin Microbiol 36, 1443-1445.
74. Herbrecht R, Denning D W, Patterson T F, Bennett. J E, Greene R E, Oestmann. J W, Kern W V, Marr K A, Ribaud P, Lortholary O, Sylvester R, Rubin R H, Wingard. J R, Stark P, Durand C, Caillot D, Tiel E, Chandrasekar P H, Hodges M R, Schlamm H T, Troke P F, de Pauw B. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347, 408-415. (Pubitemid 34851833)
75. Holland J, Young M L, Lee O, Chen A. (2003). Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 79, 249-250.
76. Horowitz B J, Edelstein S W, Lippman L, 1985 Candida tropicalis vul-vovaginitis. Obstet Gynecol 66, 229-232.
77. Hospenthal D R, Beckius M L, Floyd K L, Horvath L L, Murray C K. (2006). Presumptive identifcation of Candida species other than C albicans C krusei and C tropicalis with the chromogenic medium CHROMagar Candida. Ann Clin Microbiol Antimicrob 5, 1.
78. Hoyer L L, Fundyga R, Hecht. J E, Kapteyn. J C, Klis F M, Arnold J. (2001). Characterization of agglutinin-like sequence genes from non-albicans Candida and phylogenetic analysis of the ALS family. Genetics 157, 1555-1567.
79. Hube B, Ruchel R, Monod M, Sanglard D, Odds F C. (1998). Functional aspects of secreted Candida proteinases. Adv Exp Med Biol 436339-44-44.
80. Huttova M, Hartmanova I, Kralinsky K, Filka J, Uher J, Kurak J, Krizan S, Krcmery V. (1998). Candida fungemia in neonates treated with fuconazole: report of forty cases including eight with meningitis. Pediatr Infect Dis J 17, 1012-1015.
81. Jang S J, Han H L, Lee S H, Ryu S Y, Chaulagain B P, Moon Y L, Kim D H, Jeong O Y, Shin. J H, Moon D S, Park Y J. (2005). PFGE-based epidemiological study of an outbreak of Candida tropicalis can-diduria: the importance of medical waste as a reservoir of noso-comial infection. Jpn J Infect Dis 58, 263-267.
82. Jautova J, Viragova S, Ondrasovic M, Holoda E. (2001). Incidence of Candida species isolated from human skin and nails: a survey. Folia Microbiol (Praha). 46, 333-337.
83. Johnson E M, Davey K G, Szekely A, Warnock D W. (1995). Itraconazole susceptibilities of fuconazole susceptible and resistant isolates of fve Candida species. J Antimicrob Chemother 36, 787-793.
84. Kam A P, Xu J. (2002). Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis 43, 19-28.
85. Kleinegger C L, Lockhart S R, Vargas K, Soll D R. (1996). Frequency intensity species and strains of oral Candida vary as a function of host age. J Clin Microbiol 34, 2246-2254.
86. Klotz S A, Smith R L. (1992). Glycosaminoglycans inhibit Candida albi-cans adherence to extracellular matrix proteins. FEMS Microbiol Lett 78, 205-208.
87. Kontoyiannis D P, Vaziri I, Hanna H A, Boktour M, Tornby J, Hachem R, Bodey G P, Raad I I. (2001). Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 33, 1676-1681. (Pubitemid 33044532)
88. Krcmery V, Mrazova M, Kunova A, Grey E, Mardiak J, Jurga L, Sabo A, Sufiarsky J, Sevcikova L, Sorkovska D, West D, Trupl J, Novotny J, Mateicka F. (1999). Nosocomial candidaemias due to species other than Candida albicans in cancer patients Aetiology risk factors and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer 7, 428-431.
89. Kullberg B J, Sobel. J D, Ruhnke M, Pappas P G, Viscoli C, Rex. J H, Cleary. J D, Rubinstein E, Church L W, Brown. J M, Schlamm H T, Oborska I T, Hilton F, Hodges M R. (2005). Voriconazole versus a regimen of amphotericin B followed by fuconazole for candidae-mia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366, 1435-1442.
90. Kuse E R, Chetchotisakd P, da Cunha C A, Ruhnke M, Barrios C, Raghunadharao D, Sekhon. J S, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann A J, Ostrosky-Zeichner L, Lortholary O, Koblinger S, ekmann-Berndt H, Cornely O A. (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369, 1519-1527.
91. Kwok Y K, Tay Y K, Goh C L, Kamarudin A, Koh M T, Seow C S. (1998). Epidemiology and in vitro activity of antimycotics against can-didal vaginal/skin/nail infections in Singapore. Int J Dermatol 37, 145-149.
92. Laverdiere M, Hoban D, Restieri C, Habel F. (2002). In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50, 119-123.
93. Law D, Moore C B, Wardle H M, Ganguli L A, Keaney M G, Denning D W. (1994). High prevalence of antifungal resistance in Candida spp from patients with AIDS. J Antimicrob Chemother 34, 659-668.
94. Lecciones. J A, Lee. J W, Navarro E E, Witebsky F G, Marshall D, Steinberg S M, Pizzo P A, Walsh T J. (1992). Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14, 875-883.
95. Leroy O, Gangneux. J P, Montravers P, Mira. J P, Gouin F, Sollet. J P, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O. (2009). Epidemiology management and risk factors for death of invasive Candida infections in critical care: a multicenter prospective observational study in France (2005-2006). Crit Care Med 37, 1612-1618.
96. Leung A Y, Chim C S, Ho P L, Cheng V C, Yuen K Y, Lie A K, Au W Y, Liang R, Kwong Y L. (2002). Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 50, 316-319.
97. Leung W K, Dassanayake R S, Yau. J Y, Jin L J, Yam W C, Samaranayake L P. (2000). Oral colonization phenotypic and genotypic profles of Candida species in irradiated dentate xerostomic nasopharyngeal carcinoma survivors. J Clin Microbiol 38, 2219-2226.
98. Lin D, Lehmann P F. (1995). Random amplifed polymorphic DNA for strain delineation within Candida tropicalis. J Med Vet Mycol 33, 241-246.
99. Lopez C, Giro L, Ramos L, Ramadan S, Bulacio L. (2005). [Comparison of diferent methods for species identifcation of genus Candida]. Rev Argent Microbiol 37, 16-21.
100. Lundstrom T, Sobel J. (2001). Nosocomial candiduria: a review. Clin Infect Dis 32, 1602-1607.
101. Luque A G, Biasoli M S, Tosello M E, Binolf A, Lupo S, Magaro H M. (2009). Oral yeast carriage in HIV-infected and non-infected populations in Rosario Argentina. Mycoses 52, 53-59.
102. MacDonald L, Baker C, Chenoweth C. (1998). Risk factors for candi-demia in a children's hospital. Clin Infect Dis 26, 642-645.
103. MacFie J, O'Boyle C, Mitchell C J, Buckley P M, Johnstone D, Sudworth P. (1999). Gut origin of sepsis: a prospective study investigating associations between bacterial translocation gastric microfora and septic morbidity. Gut 45, 223-228.
104. Majithiya J, Sharp A, Parmar A, Denning D W, Warn P A. (2009). Efcacy of isavuconazole voriconazole and fuconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63, 161-166.
105. Marshall. J C, Christou N V, Meakins. J L. (1993). Te gastrointestinal tract Te "undrained abscess" of multiple organ failure. Ann Surg 218, 111-119.
106. Martin M V, Wilkinson G R, 1983 Te oral yeast fora of 10-year-old schoolchildren. Sabouraudia 21, 129-135.
107. Masood A, Sallah S. (2005). Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic defnition and treatment 1. Leuk Res 29, 493-501.
108. McCullers. J A, Flynn P M. (1998). Candida tropicalis osteomyelitis: case report and review. Clin Infect Dis 26, 1000-1001.
109. McCullers. J A, Vargas S L, Flynn P M, Razzouk B I, Shenep. J L. (2000). Candidal meningitis in children with cancer. Clin Infect Dis 31, 451-457.
110. Melo A S, Colombo A L, rthington-Skaggs B A. (2007). Paradoxical growth efect of caspofungin observed on bioflms and planktonic cells of fve diferent Candida species. Antimicrob Agents Chemother 51, 3081-3088.
111. Mikamo H, Sato Y, Tamaya T. (2000). In vitro antifungal activity of FK463 a new water-soluble echinocandin-like lipopeptide. J. Antimicrob Chemother 46, 485-487.
112. Miller D J, Mejicano G C. (2001). Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 33, 523-530.
113. Nagaraja P A, Mathew T, Shetty D P. (2005). Candida tropicalis causing Prosthetic Valve Endocarditis Indian. J Med Microbiol 23, 139-140.
114. Nguyen M H, Yu C Y. (1998). Voriconazole against fuconazole-sus-ceptible and resistant candida isolates: in-vitro efcacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 42, 253-256.
115. Nieminen M T, Uittamo J, Salaspuro M, Rautemaa R. (2009). Acetaldehyde production from ethanol and glucose by non-Candida albicans yeasts in vitro. Oral Oncol Epub 2009 Sep 29.
116. Nucci M, Colombo A L. (2007). Candidemia due to Candida tropicalis: clinical epidemiologic and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 58, 77-82.
117. Odds F C, Bernaerts R. (1994). CHROMagar Candida a new diferen-tial isolation medium for presumptive identifcation of clinically important Candida species. J Clin Microbiol 32, 1923-1929.
118. Oksuz S, Sahin I, Yildirim M, Gulcan A, Yavuz T, Kaya D, Koc A N. (2007). Phospholipase and proteinase activities in diferent Candida species isolated from anatomically distinct sites of healthy adults. Jpn J Infect Dis 60, 280-283.
119. Ozcan K, Ilkit M, Ates A, Turac-Bicer A, Demirhindi H. (2009). Performance of Chromogenic Candida Agar and CHROMagar Candida in recovery and presumptive identifcation of monofun-gal and polyfungal vaginal isolates. Med Mycol 1-6 Feb 4: [Epub ahead of print].
120. Pappas P G, Kaufman C A, Andes D Benjamin D K Jr Calandra T F, Edwards. J E Jr Filler S G, Fisher. J F, Kullberg B J, Ostrosky-Zeichner L, Reboli A C, Rex. J H, Walsh T J, Sobel. J D 2009 Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48, 503-35.
121. Pappas P G, Rex. J H, Sobel. J D, Filler S G, Dismukes W E, Walsh T J, Edwards. J E. (2004). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161-189.
122. Parazzini F, Di-Cintio E, Chiantera V, Guaschino S. (2000). Determinants of diferent Candida species infections of the genital tract in women Sporachrom Study Geoup. Eur J Obstet Gynecol Reprod Biol 93, 141-145.
123. Parke D W, Jones D B, Gentry L O, 1982 Endogenous endophthalmitis among patients with candidemia. Ophthalmology 89, 789-796.
124. Parra-Ortega B, Cruz-Torres H, Villa-Tanaca L, Hernandez-Rodriguez C. (2009). Phylogeny and evolution of the aspartyl protease family from clinically relevant Candida species. Mem Inst Oswaldo Cruz 104, 505-512.
125. Pasquale T, Tomada. J R, Ghannoun M, Dipersio J, Bonilla H. (2008). Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 61, 219.
126. Paul N, Mathai E, Abraham O C, Mathai D. (2004). Emerging microbiological trends in Candiduria. Clin Infect Dis 39, 1743-1744.
127. Pfaller M A. (1996). Nosocomial candidiasis: emerging species reservoirs and modes of transmission. Clin Infect Dis 22 Suppl, 2S89-94-94.
128. Pfaller M A, Diekema D J, 2007a Epidemiology of invasive candidia-sis: a persistent public health problem. Clin Microbiol Rev 20, 133-163.
129. Pfaller M A, Diekema D J, Gibbs D L, Newell V A, Meis. J F, Gould I M, Fu W, Colombo A L, Rodriguez-Noriega E, 2007b Results from the ARTEMIS DISK Global Antifungal Surveillance Study 1997-2005: An 8 5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by CLSI Standardized Disk Difusion Testing. J Clin Microbiol 45,1735-45.
130. Pfaller M A, Diekema D J, Jones R N, Sader H S, Fluit A C, Hollis Messer S A. (2001). International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fuconazole ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39, 3254-3259.
131. Pfaller M A, Diekema D J, Messer S A, Hollis R J, Jones R N. (2003). In Vitro Activities of Caspofungin Compared with Tose of Fluconazole and Itraconazole against 3959 Clinical Isolates of Candida spp, Including 157 Fluconazole-Resistant Isolates. Antimicrob Agents Chemother 47, 1068-1071.
132. Pfaller M A, Diekema D J, Sheehan D J. (2006). Interpretive breakpoints for fuconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19, 435-447.
133. Pfaller M A, Jones R N, Doern G V, Fluit A C, Verhoef J, Sader H S, Messer S A, Houston A, Cofman S, Hollis R J. (1999). International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35, 19-25.
134. Pfaller M A, Jones R N, Doern G V, Sader H S, Messer S A, Houston A, Cofman S, Hollis R J. (2000). Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America 1997-1998. Antimicrob Agents Chemother 44, 747-751.
135. Pfaller M A, Messer S, Jones R N. (1997). Activity of a new triazole Sch 56592 compared with those of four other antifungal agents tested against clinical isolates of Candida spp and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41, 233-235.
136. Pfaller M A, Rhine-Chalberg J, Redding S W, Smith J, Farinacci G, Fothergill A W, Rinaldi M G. (1994). Variations in fuconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 32, 59-64.
137. Presterl E, Daxbock F, Graninger W, Willinger B. (2007). Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna Austria. Clin Microbiol Infect 13, 1072-1076.
138. Rangel-Frausto M S, Houston A K, Bale M J, Fu C, Wenzel R P. (1994). An experimental model for study of Candida survival and transmission in human volunteers Eur. J Clin Microbiol Infect Dis 13, 590-595.
139. Redding S P, Rinaldi M G, Hicks. J L, 1988 Te relationship of oral Candida tropicalis infection to systemic candidiasis in a patient with leukemia Spec Care Dentist 8, 111-114.
140. Revankar S G, Kirkpatrick W R, McAtee R K, Fothergill A W, Redding S W, Rinaldi M G, Patterson T F. (1998). Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 36, 153-156.
141. Rex. J H. (1996). Editorial response: catheters and candidemia. Clin Infect Dis 22, 467-470.
142. Rex. J H, Cooper C R, Merz W G, Galgiani. J N, Anaissie E J, 1995a Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 39, 906-909.
143. Rex. J H, Rinaldi M G, Pfaller M A, 1995b Resistance of Candida species to fuconazole. Antimicrob Agents Chemother 39, 1-8.
144. Richter S S, Galask R P, Messer S A, Hollis R J, Diekema D J, Pfaller M A. (2005). Antifungal susceptibilities of Candida species causing vul-vovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43, 2155-2162.
145. Rivett A G, Perry. J A, Cohen J, 1986 Urinary candidiasis: a prospective study in hospital patients Urol Res 14, 183-186.
146. Rodriguez-Adrian L J, King R T, Tamayo-Derat L G, Miller. J W, Garcia C A, Rex. J H. (2003). Retinal lesions as clues to disseminated bacterial and candidal infections: frequency natural history and etiology. Medicine (Baltimore) 82, 187-202.
147. Roilides E, Farmaki E, Evdoridou J, Dotis J, Hatziioannidis E, Tsivitanidou M, Bibashi E, Filioti I, Sofanou D, Gil-Lamaignere C, Mueller F M, Kremenopoulos G. (2004). Neonatal candidiasis: analysis of epidemiology drug susceptibility and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 23, 745-750.
148. Roilides E, Farmaki E, Evdoridou J, Francesconi A, Kasai M, Filioti J, Tsivitanidou M, Sofanou D, Kremenopoulos G, Walsh T J. (2003). Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol 41, 735-741.
149. Roling E E, Klepser M E, Wasson A, Lewis R E, Ernst E J, Pfaller M A. (2002). Antifungal activities of fuconazole caspofungin (MK0991). and
150. Sabino R, Verissimo C, Brandao J, Alves C, Parada H, Rosado L, Paixao E, Videira Z, Tendeiro T, Sampaio P, Pais C. (2009). Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital Med Mycol 1-10 Aug 5 [Epub ahead of print].
151. Sallam A, Lynn W, McCluskey P, Lightman S. (2006). Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ter 4, 675-685.
152. Schaller M, Korting H C, Schafer W, Bastert J, Chen W, Hube B. (1999). Secreted aspartic proteinase (Sap). activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 34, 169-180.
153. Sebastiani G D, Galas F. (2001). Spondylodiscitis due to Candida tropi-calis as a cause of infammatory back pain. Clin Rheumatol 20, 435-437.
154. Shin. J H, Kee S J, Shin M G, Kim S H, Shin D H, Lee S K, Suh S P, Ryang D W. (2002). Bioflm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 40, 1244-1248.
155. Simor A E, Goswell G, Louie L, Lee M, Louie M. (1997). Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test Eur. J Clin Microbiol Infect Dis 16, 693-697.
156. Singhi S, Rao D S, Chakrabarti A. (2008). Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 9, 91-95.
157. Sipsas N V, Lewis R E, Tarrand J, Hachem R, Rolston K V, Raad I I, Kontoyiannis D P. (2009). Candidemia in patients with hema-tologic malignancies in the era of new antifungal agents (2001-2007).: stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115, 4745-4752.
158. Skiest D J, Vazquez. J A, Anstead G M, Graybill. J R, Reynes J, Ward D, Hare R, Boparai N, Isaacs R. (2007). Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44, 607-614.
159. Slavin M A. (2002). Te epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 49, Suppl 1 3-6.
160. Slavin M A, Szer J, Grigg A P, Roberts A W, Seymour. J F, Sasadeusz J, Tursky K, Chen S C, Morrissey C O, Heath C H, Sorrell A T. (2004). Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 34, 192-200.
161. Sobel. J D. (2006). Te Emergence of Non-albicans Candida Species as Causes of Invasive Candidiasis and Candidemia. Curr Infect Dis Rep 8, 427-433.
162. Sobel. J D, Kaufman C A, McKinsey D, Zervos M, Vazquez. J A, Karchmer A W, Lee J, Tomas C, Panzer H, Dismukes W E. (2000). Candiduria: a randomized double-blind study of treatment with fuconazole and placebo Te National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30, 19-24.
163. Staib P, Wirsching S, Strauss A, Morschhauser J. (2001). Gene regulation and host adaptation mechanisms in Candida albicans. Int J Med Microbiol 291, 183-188.
164. Stapleton A. (2002). Urinary tract infections in patients with diabetes. Am J Med 113 Suppl 1A, 80S-84S.
165. Stefan P, Vazquez. J A, Boikov D, Xu C, Sobel. J D, Akins R A. (1997). Identifcation of Candida species by randomly amplifed polymorphic DNA fngerprinting of colony lysates. J Clin Microbiol 35, 2031-2039.
166. Stovall W D, Pessin S B 1933 Classifcation and pathogenicity of certain monilias. Am J Clin Pathol 3, 347-365.
167. Suzuki T, Miyamae Y, Ishida I. (1991). Variation of colony morphology and chromosomal rearrangement in Candida tropicalis pK233. J Gen Microbiol 137, 7.
168. Tan T Y, Tan A L, Tee N W, Ng L S, Chee C W. (2009). Te increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses Jul 10 [Epub ahead of print].
169. Taweboon S, Taweboon B, Srithavaj T, Choonharuangdej S. (2008). Oral colonization of Candida species in patients receiving radiotherapy in the head and neck area. Quintessence Int 39, e52-e57.
170. Torres H A, Hachem R Y, Chemaly R F, Kontoyiannis D P, Raad I I. (2005). Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5, 775-785.
171. Tortorano A, Biraghi E, Astolf A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A. (2002). European Confederation of Medical Mycology (ECMM). prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51, 297.
172. Tortorano A M, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. (2006). Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27, 359-366.
173. Tumbarello M, Caldarola G, Tacconelli E, Morace G, Posteraro B, Cauda R, Ortona L. (1996). Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J Antimicrob Chemother 38. 691-699.
174. Tumbarello M, Posteraro B, Trecarichi E M, Fiori B, Rossi M, Porta R, de Gaetano D K, La S M, Spanu T, Fadda G, Cauda R, Sanguinetti M. (2007). Bioflm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 45, 1843-1850.
175. Vanden A A, de M H, Ahariz M, Perraudin. J P, Beyer I, Courtois P. (2008). Denture contamination by yeasts in the elderly. Gerodontology 4, 222-8.
176. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara. J P. (2005). Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother 49. 4608-4615.
177. Vigouroux S, Morin O, Moreau P, Harousseau. J L, Milpied N. (2006). Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. Haematologica 91, 717-718.
178. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De-Pauw B, Meunier F. (1999). Candidemia in cancer patients: a prospective multicenter surveillance study by the Invasive Fungal Infection Group (IFIG). of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28, 1071-1079.
179. Vogel C, Rogerson A, Schatz S, Laubach H, Tallman A, Fell J. (2007). Prevalence of yeasts in beach sand at three bathing beaches in South Florida. Water Res 41, 1915-1920.
180. Wang. J L, Chang S C, Hsueh P R, Chen Y C. (2004). Species distribution and fuconazole susceptibility of Candida clinical isolates in a medical center in 2002. J Microbiol Immunol Infect 37, 236-241.
181. Warn P A, Morrissey J, Moore C B, Denning D W. (2000). In vivo activity of amphotericin B lipid complex in immunocompromised mice against fuconazole-resistant or fuconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother 44, 2664-2671.
182. Warn P A, Sharp A, Morrissey G, Denning D W. (2002). In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J. Antimicrob Chemother 50, 1071-1074.
183. Warn P A, Sharp A, Morrissey G, Denning D W. (2005). Activity of ami-nocandin (IP960). compared with amphotericin B and fucona-zole in a neutropenic murine model of disseminated infection caused by a fuconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 56, 590-593.
184. Weinberger M, Leibovici L, Perez S, Samra Z, Ostfeld I, Levi I, Bash E, Turner D, Goldschmied-Reouven A, Regev-Yochay G, Pitlik S D, Keller N. (2005). Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 61, 146-154.
185. Wingard. J R. (1995). Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 20, 115-125.
186. Wise G J. (2001). Genitourinary fungal infections: a therapeutic conundrum. Expert Opin Pharmacother 2, 1211-1226.
187. Wisplinghof H, Bischof T, Tallent S M, Seifert H, Wenzel R P, Edmond M B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317.
188. Wolfson. J S, Sober A J, Rubin R H, 1985 Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore ) 64, 115-133.
189. Yang C W, Barkham T M, Chan F Y, Wang Y. (2003). Prevalence of Candida Species Including Candida dubliniensis in Singapore. J Clin Microbiol 41, 472-474.
190. Yang Y L, Cheng M F, Wang C W, Wang A H, Cheng W T, Lo H J. (2009). Te distribution of species and susceptibility of amphotericin B and fuconazole of yeast pathogens isolated from sterile sites in Taiwan. Med Mycol 1-7.
191. Yang Y L, Wang A H, Wang C W, Cheng W T, Li S Y, Lo H J. (2008). Susceptibilities to amphotericin B and fuconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Diagn Microbiol Infect Dis 61, 175-180.
192. Yap H Y, Kwok K M, Gomersall C D, Fung S C, Lam T C, Leung P N, Hui M, Joynt G M. (2009). Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J 15, 255-261.
193. Yucesoy M, Ozbek O A, Marol S. (2005). Comparison of three difer-ential media for the presumptive identifcation of yeasts. Clin Microbiol Infect 11, 245-247.
194. Zaas A K, Dodds Ashley E S, Alexander B D, Johnson M D, Perfect. J R. (2006). Caspofungin for invasive candidiasis at a tertiary care medical center. Am J Med 119, 993-996.
195. Zaugg C, Borg-von-Zepelin M, Reichard U, Sanglard D, Monod M. (2001). Secreted aspartic proteinase family of Candida tropicalis. Infect Immun 69, 405-412.
196. Zedtwitz-Liebenstein K, Gabriel H, Willinger B, Ehringer H, Polterauer P, Graninger W. (2001). Prosthetic valve endocarditis due to Candida tropicalis complicated by multiple pseudoaneu-rysms. Infection 29, 177-179.